trending Market Intelligence /marketintelligence/en/news-insights/trending/QgWOsxYnTkUZo5nATJONlg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Motif Bio closes placing to fund novel antibiotic development

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Motif Bio closes placing to fund novel antibiotic development

Motif Bio PLC closed its conditional placing of new ordinary shares to fund the development of iclaprim, the company's novel antibiotic candidate.

A total of 66,666,667 new ordinary shares of 1 penny each in the capital of the company was placed with new and existing investors at a price of 30 pence apiece, for a total of £20 million before expenses. The placing is conditional on the passing of certain resolutions by Motif Bio shareholders at the company's June 22 general meeting.

The placing shares will represent 34% of the issued ordinary share capital of the company before the placing.

The company's issued share capital will comprise 262,878,775 ordinary shares of 1 penny each following the issue of the placing shares. The total number of voting rights in Motif Bio will be 262,878,775.

Peel Hunt LLP is acting as book runner and Northland Capital Partners Ltd. is acting as co-lead manager. Peel Hunt is acting as nominated adviser to the company.